Top

Clinical Orthopaedics and Related Research®

Published in:

01-06-2017 | Basic Research

Do Mesenchymal Stem Cells Derived From Atypical Lipomatous Tumors Have Greater Differentiation Potency Than Cells From Normal Adipose Tissues?

Authors: Hiroyuki Inatani, MD, Norio Yamamoto, MD, PhD, Katsuhiro Hayashi, MD, PhD, Hiroaki Kimura, MD, PhD, Akihiko Takeuchi, MD, PhD, Shinji Miwa, MD, PhD, Takashi Higuchi, MD, Kensaku Abe, MD, Yuta Taniguchi, MD, Satoshi Yamada, MD, PhD, Kiyofumi Asai, MD, PhD, Takanobu Otsuka, MD, PhD, Hiroyuki Tsuchiya, MD, PhD

Published in: Clinical Orthopaedics and Related Research® | Issue 6/2017

Abstract

Background

The p53 protein in mesenchymal stem cells (MSCs) regulates differentiation to osteogenic or adipogenic lineage. Because p53 function is depressed in most malignancies, if MSCs in malignancy also have p53 hypofunction, differentiation therapy to osteogenic or adipogenic lineage may be an effective treatment. We therefore wished to begin to explore this idea by evaluating atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) cells, because murine double minute 2 (MDM2) gene amplification, which leads to p53 hypofunction, is found in almost all ALT/WDLs.

Questions/purposes

We compared osteogenic and adipogenic differentiation potency between MSCs isolated and cultured from normal adipose tissues and ALT/WDLs from the same patients.

Methods

During tumor resections in six patients with ALT/WDL, we analyzed 3 mL of tumor, and for comparison, we harvested a similar amount of normal-appearing subcutaneous adipose tissue from an area remote from the tumor for comparison. Adipogenic differentiation potency was quantitatively assessed using spectrometry after oil red O staining. Osteogenic differentiation potency was semiquantitatively assessed by measuring a specific colored area after alkaline phosphatase (ALP) and alizarin red S staining. ALP is related to preosseous cellular metabolism, and alizarin red is related to calcium deposits in cell culture. There were three observers for each assessment, and each assessment (including induced-differentiation and histologic analysis) was performed in duplicate. We then analyzed the mechanism of the difference of osteogenic differentiation potency using the MDM2-specific inhibitor Nutlin-3 at various concentrations.

Results

In terms of adipogenic differentiation potency, contrary to our expectations, more fatty acid droplets were observed in MSCs derived from normal fat than in MSCs derived from ALT/WDL, although we found no significant difference between MSCs derived from ALT/WDL and MSCs derived from normal fat; the mean differentiation potency values (normal adipose tissue versus ALT/WDL) (± SD) were 0.34 (SD, ± 0.13; 95% CI, 0.24–0.44) versus 0.25 (SD, ± 0.10; 95% CI, 0.18–0.33; p = 0.22). By contrast, we found greater osteogenic differentiation potency in MSCs derived from ALT/WDL than in MSCs derived from normal fat. The mean differentiation potency values (normal adipose tissue versus ALT/WDL) (±SD) based on ALP staining was 1.0 versus 17 (SD, ± 36; 95% CI, −2.8 to 38; p = 0.04). However, we found no differences based on alizarin red S staining; mean differentiation potency value (normal adipose tissue versus ALT/WDL) (± SD) was 1.0 versus 4.2 (SD, ± 4.8; 95% CI, 1.3–7.2; p = 0.58). The gap of osteogenic differentiation potency between MSCs from normal adipose tissue and ALT/WDL was decreased as MDM2-inhibitor Nutlin-3 concentration increased.

Conclusions

MSCs derived from ALT/WDL had higher osteogenic differentiation potency based on ALP staining, which disappeared as Nutlin-3 concentration increased, suggesting that could be caused by amplified MDM2 in ALT/WDL. Future laboratory studies might mechanistically confirm the gene and protein expression, and based on the mechanism of the gap of differentiation potency, if p53 contrast between MSCs in tumor and normal tissue could be stimulated, less-toxic and more-effective differentiation therapy to MSCs in malignancies might be developed.

Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999;96:3951–3956.CrossRefPubMedPubMedCentral

Gopinathan L, Hannon DB, Peters JM, Heuvel JPV. Regulation of peroxisome proliferator-activated receptor-α by MDM2. Toxicol Sci. 2009;108:48–58.CrossRefPubMed

Goto T, Lee JY, Teraminami A, Kim YI, Hirai S, Uemura T, Inoue H, Takahashi N, Kawada T. Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. J Lipid Res. 2011;52:873–884.CrossRefPubMedPubMedCentral

Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 1997;25:151–157.CrossRefPubMedPubMedCentral

Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318–1327.CrossRefPubMed

Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53.CrossRefPubMed

Kimura H, Dobashi Y, Nojima T, Nakamura H, Yamamoto N, Tsuchiya H, Ikeda H, Sawada-Kitamura S, Oyama T, Ooi A. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics. Int J Clin Exp Pathol. 2013;6:1306–1316.PubMedPubMedCentral

Matsumoto T, Kano K, Kondo D, Fukuda N, Iribe Y, Tanaka N, Matsubara Y, Sakuma T, Satomi A, Otaki M, Ryu J, Mugishima H. Mature adipocyte-derived dedifferentiated fat cells exhibit multilineage potential. J Cell Physiol. 2008;215:210–222.CrossRefPubMed

Meek DW. Regulation of the p53 response and its relationship to cancer. Biochem J. 2015;469:325–346.CrossRefPubMed

10.

Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R, Rotter V. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One. 2008;3:e3707.CrossRefPubMedPubMedCentral

11.

Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705–708.CrossRefPubMed

12.

Puzio-Kuter AM, Laddha SV, Castillo-Martin M, Sun Y, Cordon-Cardo C, Chan CS, Levine AJ. Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma. Cell Death Differ. 2015;22:1785–1791.CrossRefPubMedPubMedCentral

13.

Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13:1133–1140.CrossRefPubMed

14.

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111.CrossRefPubMed

15.

Roessner A, Schneider-Stock R, Radig K, Neumann W, Mittler U. Alterations of p53 gene in soft tissue and bone tumors. Genet Diagn Pathol. 1997;143:1–13.

16.

Solozobova V, Blattner C. p53 in stem cells. World J Biol Chem. 2011;2:202–214.CrossRefPubMedPubMedCentral

17.

Tataria M, Quarto N, Longaker MT, Sylvester KG. Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells. J Pediatr Surg. 2006;41:624–632.CrossRefPubMed

18.

Taubert H, Meye A, Wurl P. Soft tissue sarcomas and p53 mutations. Mol Med. 1998;4:365–372.PubMedPubMedCentral

19.

Taubert H, Schmidt H, Wurl P, Hinze R, Meye A, Bache M, Berger D, Holzhausen H, Dralle H, Rath F. Morphological and molecular characterization of an undifferentiated soft tissue sarcoma cell line and derivative clones. Int J Oncol. 1997;11:521–526.PubMed

20.

Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A. 1997;94:237–241.CrossRefPubMedPubMedCentral

21.

Weaver J, Kelly DE, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, Rubin BP, Skacel M. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol. 2008;21:943–949.CrossRefPubMed

22.

Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med. 1997;121:395–399.PubMed

Title: Do Mesenchymal Stem Cells Derived From Atypical Lipomatous Tumors Have Greater Differentiation Potency Than Cells From Normal Adipose Tissues?
Authors: Hiroyuki Inatani, MD
Norio Yamamoto, MD, PhD
Katsuhiro Hayashi, MD, PhD
Hiroaki Kimura, MD, PhD
Akihiko Takeuchi, MD, PhD
Shinji Miwa, MD, PhD
Takashi Higuchi, MD
Kensaku Abe, MD
Yuta Taniguchi, MD
Satoshi Yamada, MD, PhD
Kiyofumi Asai, MD, PhD
Takanobu Otsuka, MD, PhD
Hiroyuki Tsuchiya, MD, PhD
Publication date: 01-06-2017
Publisher: Springer US
Published in: Clinical Orthopaedics and Related Research® / Issue 6/2017
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI: https://doi.org/10.1007/s11999-017-5259-z

At a glance: The STEP trials

Springer Medicine

Do Mesenchymal Stem Cells Derived From Atypical Lipomatous Tumors Have Greater Differentiation Potency Than Cells From Normal Adipose Tissues?

Abstract

Background

Questions/purposes

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Questions/purposes

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2017

Is There an Association Between Hemoglobin A1C and Deep Postoperative Infection After TKA?

Editorial: Federal Restrictions on Gun Research Should Be Lifted

Erratum to: What is the Accuracy of Nuclear Imaging in the Assessment of Periprosthetic Knee Infection? A Meta-analysis

CORR Insights ® : Anterolateral Ligament of the Knee Shows Variable Anatomy in Pediatric Specimens

ArtiFacts: Corporal Robert O. Burkhardt’s Right Leg

Does the Critical Shoulder Angle Correlate With Rotator Cuff Tear Progression?